BioSpace

J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial

Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.

By BioSpace

1 min read
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights